Cargando…

Opioid-Induced Psychosis in a Patient With Sickle Cell Disease

Sickle cell disease (SCD) is a common inherited hemoglobin disorder in which people have atypical hemoglobin, known as hemoglobin S. It is highly prevalent in non-Hispanic Blacks and people of Arab descent. It causes a distortion of the shape of red blood cells, leading to occlusion of blood vessels...

Descripción completa

Detalles Bibliográficos
Autores principales: Tumenta, Terence, Thanju, Amod, Perera, Pradilka, Kallikkadan, Jisha, Fouron, Patrice, Olupona, Tolulope
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270061/
https://www.ncbi.nlm.nih.gov/pubmed/34277180
http://dx.doi.org/10.7759/cureus.15557
_version_ 1783720720681926656
author Tumenta, Terence
Thanju, Amod
Perera, Pradilka
Kallikkadan, Jisha
Fouron, Patrice
Olupona, Tolulope
author_facet Tumenta, Terence
Thanju, Amod
Perera, Pradilka
Kallikkadan, Jisha
Fouron, Patrice
Olupona, Tolulope
author_sort Tumenta, Terence
collection PubMed
description Sickle cell disease (SCD) is a common inherited hemoglobin disorder in which people have atypical hemoglobin, known as hemoglobin S. It is highly prevalent in non-Hispanic Blacks and people of Arab descent. It causes a distortion of the shape of red blood cells, leading to occlusion of blood vessels and thus tissue hypoxia and injury. The resultant infarction/reperfusion, in turn, causes fatigue and pain. Patients with SCD require constant analgesic medications for pain management. In the general population, opioids are amongst the most prescribed medications for pain management and the trend has been gradually growing during the past two decades. Side effects commonly associated with opioids are gastrointestinal and central nervous system-related, with up to 80% of patients experiencing at least one adverse effect. We report the case of a 36-year-old male patient who has a history of cannabis use and no prior psychiatric history, who developed acute psychosis while receiving a high dose of hydromorphone for sickle cell pain crisis. This case contributes to the growing literature about opioid-induced psychosis and also explores psychosis in sickle cell disease. Understanding the pharmacology and potential side effects of opioids is critical given the increasing number of patients using prescribed and illicit opioids.
format Online
Article
Text
id pubmed-8270061
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-82700612021-07-15 Opioid-Induced Psychosis in a Patient With Sickle Cell Disease Tumenta, Terence Thanju, Amod Perera, Pradilka Kallikkadan, Jisha Fouron, Patrice Olupona, Tolulope Cureus Internal Medicine Sickle cell disease (SCD) is a common inherited hemoglobin disorder in which people have atypical hemoglobin, known as hemoglobin S. It is highly prevalent in non-Hispanic Blacks and people of Arab descent. It causes a distortion of the shape of red blood cells, leading to occlusion of blood vessels and thus tissue hypoxia and injury. The resultant infarction/reperfusion, in turn, causes fatigue and pain. Patients with SCD require constant analgesic medications for pain management. In the general population, opioids are amongst the most prescribed medications for pain management and the trend has been gradually growing during the past two decades. Side effects commonly associated with opioids are gastrointestinal and central nervous system-related, with up to 80% of patients experiencing at least one adverse effect. We report the case of a 36-year-old male patient who has a history of cannabis use and no prior psychiatric history, who developed acute psychosis while receiving a high dose of hydromorphone for sickle cell pain crisis. This case contributes to the growing literature about opioid-induced psychosis and also explores psychosis in sickle cell disease. Understanding the pharmacology and potential side effects of opioids is critical given the increasing number of patients using prescribed and illicit opioids. Cureus 2021-06-09 /pmc/articles/PMC8270061/ /pubmed/34277180 http://dx.doi.org/10.7759/cureus.15557 Text en Copyright © 2021, Tumenta et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Tumenta, Terence
Thanju, Amod
Perera, Pradilka
Kallikkadan, Jisha
Fouron, Patrice
Olupona, Tolulope
Opioid-Induced Psychosis in a Patient With Sickle Cell Disease
title Opioid-Induced Psychosis in a Patient With Sickle Cell Disease
title_full Opioid-Induced Psychosis in a Patient With Sickle Cell Disease
title_fullStr Opioid-Induced Psychosis in a Patient With Sickle Cell Disease
title_full_unstemmed Opioid-Induced Psychosis in a Patient With Sickle Cell Disease
title_short Opioid-Induced Psychosis in a Patient With Sickle Cell Disease
title_sort opioid-induced psychosis in a patient with sickle cell disease
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270061/
https://www.ncbi.nlm.nih.gov/pubmed/34277180
http://dx.doi.org/10.7759/cureus.15557
work_keys_str_mv AT tumentaterence opioidinducedpsychosisinapatientwithsicklecelldisease
AT thanjuamod opioidinducedpsychosisinapatientwithsicklecelldisease
AT pererapradilka opioidinducedpsychosisinapatientwithsicklecelldisease
AT kallikkadanjisha opioidinducedpsychosisinapatientwithsicklecelldisease
AT fouronpatrice opioidinducedpsychosisinapatientwithsicklecelldisease
AT oluponatolulope opioidinducedpsychosisinapatientwithsicklecelldisease